Published: November 5, 2025 at 8:01 am
Cambridge Cognition Holdings plc, which makes digital health products to advance brain health research and treatment, has announced a series of leadership changes.
Joint managing director Alex Livingstone-Learmonth will leave the company in the new year to pursue new opportunities, with his fellow joint MD Rob Baker named CEO.
Prior to joining Cambridge Cognition Holdings in 2022, Baker held several senior roles at Amazon including leading large operational teams to scale Alexa voice technology improvements and its privacy and security operations. He was also responsible for regional Amazon Echo device sales.
Dr Steven Powell, who will retire as non-executive chair of the board at the next annual general meeting, will be succeeded in the role by non-exec director Nick Rodgers.
Rodgers is an adviser to gene therapy company Santo Therapeutics and was until May 2024 chair of SEHTA, a health technology membership and networking organisation supporting businesses in the HealthTech sector.
He has also served as chair of Destiny Pharma plc, a developer of novel anti-infective products; ZPN Energy Limited, a developer of battery storage technologies and systems; and Oxford BioMedica plc, a pioneer of gene and cell therapy.